Abiopharma

🔍 Clark Kyle (Executive)

Company: BETA Technologies, Inc. (BETA)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Sold 67,296 shares of Class A common stock at $18.1216 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: false | shares_owned_after: 748,915.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,965 shares of Class A common stock at $18.1216 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: false | shares_owned_after: 49,746.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Holds 0 shares of Class A common stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By The Burrow Trust | shares_owned_after: 1,624,907.00 | Footnotes: F3
• Holds 0 shares of Class A common stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: By The Godric's Hollow Trust | shares_owned_after: 5,719,837.00 | Footnotes: F3

Footnotes:

• F1: Mandatory sale to cover tax liability associated with the settlement of performance-based restricted stock units.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.6100 to $19.6099, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
• F3: The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• REMARKS: Chief Executive Officer and President